Under 10% of patients eligible to benefit from weight-loss injections like Wegovy are able to get them, caution the WHO as it releases its first advice on the medications.
With over a billion individuals worldwide now living with obesity, it is calling for increased and just access to these injectable treatments.
Based on projections, more than two billion will be living with obesity by 2030 unless action is taken.
"Our new guidelines affirms that excess weight is a long-term condition that can be addressed with thorough and ongoing support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are major obstacles to universal availability to the jabs that can aid individuals in losing significant weight, says the body.
Skinny Jab Supply Crisis
Even in the present best projected case, the production of these medications might only reach about 100 million people – fewer than 10% of the global need, as stated by the health organization.
The recommendation urges countries and companies to widen availability, by approaches like licensing agreements.
Exclusive production rights on a key compound – the main ingredient of a leading brand – is scheduled to end in multiple countries in 2026.
The Way Weight-Loss Injections Function
These medications replicate a body's own hormone to slow digestion, reduce hunger and boost satiety so individuals eat less.
Patients typically see weight reduction in the initial weeks of commencing the weekly injections.
Evidence points to users may regain a significant portion a year later of halting the drug, as their usual food cravings return.
To be carrying excess weight increases your chance for developing medical conditions, such as diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity affects people in countries worldwide and was associated with millions of fatalities worldwide in 2024, according to the WHO.
